IN8bio
INAB
16 hedge funds and large institutions have $2.77M invested in IN8bio in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
14% more capital invested
Capital invested by funds: $2.42M → $2.77M (+$342K)
0% more ownership
Funds ownership: 0.16% → 0.16% (+0%)
6% less funds holding
Funds holding: 17 → 16 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$152K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$24.7K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$20.8K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$18.7K |
| 5 |
BlackRock
New York
|
+$15.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Precept Management
Dallas,
Texas
|
-$101K |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$70.1K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$30K |
| 4 |
UAS
United Asset Strategies
Garden City,
New York
|
-$28K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.85K |
INAB Hedge Fund Activity: Q4 2022 in Review
16 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q4 2022, worth a combined $2.77M — up 14% from $2.42M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of INAB and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Rock Creek Group, opening a new position worth an estimated $152K. The largest seller was Precept Management, exiting entirely with an estimated $101K sold.
- 16 institutional investors held IN8bio (INAB) as of Q4 2022, down from 17 in Q3 2022.
- Funds reported $2.77M of IN8bio stock for Q4 2022, up 14% quarter-over-quarter.
- 4 funds opened new IN8bio positions in Q4 2022 and 5 closed out, a net change of -1 holder.
- The largest IN8bio buyer in Q4 2022 was Rock Creek Group, an estimated $152K added.
- The largest IN8bio seller in Q4 2022 was Precept Management, an estimated $101K sold.
Based on aggregated 13F filings for Q4 2022.